These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Non-coding RNA in drug resistance of hepatocellular carcinoma. Ding B; Lou W; Xu L; Fan W Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30224380 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Hepatobiliary Cancers. Nault JC; Villanueva A Hepatology; 2021 Jan; 73 Suppl 1():115-127. PubMed ID: 32045030 [TBL] [Abstract][Full Text] [Related]
11. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance. Yang S; Wang XQ BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069 [TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma. Likhitrattanapisal S; Tipanee J; Janvilisri T Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818 [TBL] [Abstract][Full Text] [Related]
13. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Marin JJG; Macias RIR; Monte MJ; Romero MR; Asensio M; Sanchez-Martin A; Cives-Losada C; Temprano AG; Espinosa-Escudero R; Reviejo M; Bohorquez LH; Briz O Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585893 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. Park SY; Han J; Kim JB; Yang MG; Kim YJ; Lim HJ; An SY; Kim JH Eur J Cancer; 2014 Jan; 50(2):341-50. PubMed ID: 24161763 [TBL] [Abstract][Full Text] [Related]
15. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma. Li G; Dong S; Qu J; Sun Z; Huang Z; Ye L; Liang H; Ai X; Zhang W; Chen X Liver Int; 2010 Apr; 30(4):585-92. PubMed ID: 19780956 [TBL] [Abstract][Full Text] [Related]
16. Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects. Lei YR; He XL; Li J; Mo CF Front Biosci (Landmark Ed); 2024 Feb; 29(2):52. PubMed ID: 38420802 [TBL] [Abstract][Full Text] [Related]
17. Dysregulated Expression of MITF in Subsets of Hepatocellular Carcinoma and Cholangiocarcinoma. Nooron N; Ohba K; Takeda K; Shibahara S; Chiabchalard A Tohoku J Exp Med; 2017 Aug; 242(4):291-302. PubMed ID: 28794318 [TBL] [Abstract][Full Text] [Related]
18. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611 [TBL] [Abstract][Full Text] [Related]
19. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway. Huang WC; Tung SL; Chen YL; Chen PM; Chu PY BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298 [TBL] [Abstract][Full Text] [Related]
20. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells. Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]